Everyday concept detection in visual lifelogs: validation, relationships and trends

The Microsoft SenseCam is a small lightweight wearable camera used to passively capture photos and other sensor readings from a user's day-to-day activities. It can capture up to 3,000 images per day, equating to almost 1 million images per year. It is used to aid memory by creating a personal multimedia lifelog, or visual recording of the wearer's life. However the sheer volume of image data captured within a visual lifelog creates a number of challenges, particularly for locating relevant content. Within this work, we explore the applicability of semantic concept detection, a method often used within video retrieval, on the novel domain of visual lifelogs. A concept detector models the correspondence between low-level visual features and high-level semantic concepts (such as indoors, outdoors, people, buildings, etc.) using supervised machine learning. By doing so it determines the probability of a concept's presence. We apply detection of 27 everyday semantic concepts on a lifelog collection composed of 257,518 SenseCam images from 5 users. The results were then evaluated on a subset of 95,907 images, to determine the precision for detection of each semantic concept. We conduct further analysis on the temporal consistency, co-occurance and trends within the detected concepts to more extensively investigate the robustness of the detectors within this novel domain. We additionally present future applications of concept detection within the domain of lifelogging

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Characteristics and Complications of Anogenital Infantile Hemangiomas: A Multicenter Retrospective Analysis

IMPORTANCE: Infantile hemangiomas (IHs) of the anogenital region remain poorly characterized. OBJECTIVE: To examine the distribution, ulceration rate, and associated congenital anomalies of anogenital IHs. METHODS: Retrospective study at 8 tertiary referral centers. RESULTS: A total of 435 infants with an IH of the anogenital region were enrolled (319 female, [73%]). Congenital anomalies were present in 6.4% (n=28) of infants with an anogenital IH. Segmental/partial segmental anogenital IHs ulcerated in 72% (n=99 of 138) of infants, while 45% (n=133 of 297) of focal anogenital IHs experienced ulceration (P= \u3c.001). In a multivariable logistic regression analysis, segmental/partial segmental morphology (adjusted odds ratio [aOR] 2.70, 95% confidence interval [CI] 1.60-4.64), mixed type (aOR 3.44, 95% CI 2.01-6.07), perianal (aOR 3.01, 95% CI 1.53-6.12) and buttocks location (aOR 2.08, 95% CI 1.17-3.76), had an increased odds of ulceration. Segmental/partial segmental IHs of the genitalia were confined to distinct anatomic territories and were predominantly distributed unilaterally with a linear demarcation at the perineal raphe. LIMITATIONS: Possible selection bias given recruitment at tertiary referral centers. CONCLUSIONS AND RELEVANCE: This study improves our understanding of high-risk features of anogenital IHs and demonstrates that genital segmental/partial segmental IHs develop within distinct anatomic territories